Showing 6 results for Zhand
Abbasi A (md), Tajbakhsh R (md), Kabotari M, Zhand S (msc), Tabarraei A (phd), ,
Volume 6, Issue 1 (spring-summer[PERSIAN] 2012)
Abstract
Abstract Background and objectives: Hepatitis B virus infection is a major health problem in worldwide. The prevalence of Occult and chronic HBV in hemodialysis patients is higher than standard in developing countries. People with occult HBV are negative for HBV surface antigen (HBsAg) but positive for HBV-DNA. We aimed to evaluate occult hepatitis B infection in patients under hemodialysis in Panje-Azar hospital in Gorgan. Material and Methods: In this study, taken place from 2009 to 2010, the participants were 100 hemodialysis patients with administration of complete HBV vaccination with negative test for HBsAg. After preparing 10 milliliter blood sample, HBV DNA testing was performed by polymerase chain reaction (PCR). Result: The mean age of the patients is 54.60 years. They are male (48%) and female (52%). They have been under hemodialysis for 48 months, averagely. There has not been any HBV-DNA in HBsAg negative patients under hemodialysis. The rate of occult hepatitis B infection in these end stage renal disease (ESRD) patients was zero. Conclusion: Results indicate that there is no any occult HBV infection in ESRD patients under hemodialysis in Gorgan, which is similar to some studies. The results could be justified by complete vaccination of the patients. Key words: Occult Hepatitis B, Hemodialysis, HBsAg, Gorgan
S Zhand, A Tabaraei, A Moradi, F Fotoohi, N Javid, M Bazoori, E Haji Mohammadi, A Ghaemi,
Volume 8, Issue 2 (summer 2014[PERSIAN] 2014)
Abstract
Abstract
Background and Objective: The emergence of a novel H1N1influenza A virus of animal origin with transmissibility from human to human poses pandemic concern. Current subtypes of Seasonal influenza A viruses spread in human are influenza A H1N1 influenza A H3N2 and influenza type B viruses. The aim of this study was to determine current strains of the H3N2 and new H1N1 subtypes of influenza A virus from patients suspected influenza infection in 2009 flu pandemic in Golestan province, Iran.
Material and Methods: In this descriptive study, respiratory samples (n = 153) from patients with acute respiratory symptoms were collected in 2009 flu pandemic applied during 2009 pandemic influenza in Golestan province. After reverse transcription of extracted viral RNA, PCR was developed for both H1N1and H3N2subtypes using CDC specific primers.
Results: The mean age of patients was 16.59. Of them 45.1% were male. Thirteen (8.49%) were infected with seasonal influenza H1N1 and 25(16.33%) with seasonal H3N2influenza.
Conclusion: The rate of infection with seasonal H1N1and H3N2is similar to other studies reported from Iran, but lower than the rate reported from other parts of the world.
Key Words: Influenza A Virus, H1N1, H3N2, RT-PCR, Iran
Rezanezhadi, M, Tabarraei, A, Zhand, S, Moradi, A, Nezamzade, R, Vakili, Ma,
Volume 8, Issue 5 (winter[PERSIAN] 2015)
Abstract
Abstract Background and Objective: Lamivudine is the first orally available drug approved for treatment of chronic hepatitis B. Mutations at the YMDD and FLLAQ motifs in the domains of HBV polymerase gene contribute resistance to lamivudine. This study was aimed to determine the rate of YMDD and FLLAQ mutants in hepatitis B patients in Golestan Province, Iran. Material and methods: In this cross sectional study, 120 patients with chronic HBV infection were recruited. Of them, 55 were treated and 65 untreated with Lamivudine. HBV DNA extractions from plasma and polymerase chain reaction (PCR) were performed. For detection of Lamivudine mutants direct sequencing and alignment of products were applied using reference sequence from Gene Bank database. Results: the average age of patients was 36.31±10.07, which 35% of them were female and 65% were male. Mutations at the YMDD and FLLAQ motifs in the domains of HBV polymerase gene were detected in 12 of 55 patients (21.81%) treated with Lamivudine while no mutation was observed in in untreated patients. The YMDD and FLLAQ mutants were detected in 9.16% (11/120) and 0.83% (1/120) of chronic HBV patients, respectively. Conclusion: Usual HBV mutations, which play an important role in lamivudine resistance, detected in this study are similar to other studies. Key words: Hepatitis B Viruse, YMDD Mutation, Lamivudine, Iran.
Farzane Salarneia , Sare Zhand , Behnaz Khodabakhshi , Alijan Tabarraei , Mohammad Ali Vakili , Naeme Javid , Masoud Bazori , Abdolvahab Moradi ,
Volume 10, Issue 1 (Jan,Feb 2016 2016)
Abstract
Abstract
Background and objective: Hepatitis B virus (HBV) is a DNA virus with high tendency toward hepatic tissue. There are currently about 3 million HBV-infected people and 350 to 400 million chronic carriers of this virus in the world. X protein plays a role in the over-expression of oncogenes, carcinogenicity of liver cells and overlaps with the basal core promoter of the virus. Mutations at specific nucleotides of this region increase viral replication and liver disease progression. The aim of this study was to investigate the frequency of mutations at nucleotides 1762, 1764 and 1766 of HBV X gene in patients with chronic hepatitis B and hepatitis B-related cirrhosis.
Methods: In this study, 102 patients including 68 chronic hepatitis patients and 34 patients with hepatitis B-related cirrhosis were enrolled. After DNA extraction, HBV X gene was amplified and sequenced using Semi Nested-PCR. Obtained gene sequences were compared with the standard sequence of HBV virus X gene available in the gene bank (Okamoto AB033559). Then, the mutations in the gene X of HBV were identified.
Results: Comparison of the standard sequence with sequences obtained from patients showed the presence of A1762T / G1764A mutation in 12 chronic (17.64%) and 13 cirrhotic (38.23%) patients. Also, C1766G / G1764T mutations were found in 8.23% of chronic patients and 17.64% of cirrhotic patients.
Conclusion: A1762T / G1764A mutations in the overlapping region of the basal core promoter with gene X C-terminal may lead to liver disease progression from chronic hepatitis to cirrhosis, by changing the amino acid sequence of the X protein.
Ali Varasteh Moradi , Sedigheh Zhand ,
Volume 10, Issue 3 (May-Jun 2016 2016)
Abstract
ABSTRACT
Background and Objective: Glycyrrhizaglabra L. is one of the most widely used medicinal herbs in Golestan province that is known for its anti-inflammatory, carminative, antiviral, anti-infection and anti-ulcer properties in Iranian traditional medicine. This study aimed to assess the anti-bacterial and anti-oxidative activity of G. glabrafrom the Golestan province.
Methods: The rip root of the plant was collected in autumn 2013. The ethanolic extract of the plant was prepared by maceration method. The anti-oxidative property of the plant was assessed by total antioxidant capacity (TAC), reducing power (RP) and 1, 1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging capacity assays. The anti-bacterial activity was assessed using agar-well diffusion method and the minimum inhibitory concentration (MIC) assay.
Results: The ethanolic extract of G. glabrahad relatively high anti-oxidative activity with IC50 value of 130 µg/ml, especially in the DPPH method. The extract also exhibited high anti-bacterial activity against the following Gram-positive bacteria: Staphylococcus aureus (21.1±0.7 mm), Staphylococcus epidermidis (19.6±0.2 mm), Bacillus subtilus (19.3±0.6 mm), followed by Escherichia coli (12.1±0.8 mm), Enterococcus faecalis (13.2±0.1 mm) and Kelebsiellapneumoniae (11.5±0.4 mm) with MIC values in the range of 31 - 132 mg. mL-1.
Conclusion: According to results, the root extract of G.glabrais a good source of antioxidant compounds with suitable anti-bacterial activity, which can be used as natural anti-infection and anti-inflammatory agent for treatment of many diseases.
Ahmad Hosseinzadeh Adli , Chiman Karami , Sareh Zhand , Reza Talei , Abdolvahab Moradi ,
Volume 10, Issue 4 (Jul-Aug 2016 2016)
Abstract
ABSTRACT
Background and objectives: Globally, about one third of the population has been infected with Hepatitis B virus (HBV) and more than 400 million people have become chronically infected. Nearly, 20-25% of all carriers develop serious liver diseases such as cirrhosis, chronic hepatitis and hepatocellular carcinoma (HCC). According to the World Health Organization, HBV infection causes more than one million deaths every year. Co-infection with Human Immunodeficiency virus (HIV) and HBV is common, since both viruses have the same routes of transmission. Approximately 10 -15% of HIV-infected individuals develop chronic hepatitis B. The risk of liver diseases-related deaths is also higher in the co-infected patients. According to previous studies, mutation of the pre-core (PC) and basal-core promoter (BCP) regions may play an important role in development of HBV-related HCC and severe liver disease. The aim of this study was to investigate mutations in the BCP, PC and core regions of HBV in HIV-positive patients.
Methods: DNA was extracted using commercial kits to determine the BCP, PC/core mutations in 124 HIV/HBV co-infected patients (32.4% female and 67.6% male). Polymerase chain reaction (PCR) was performed using specific primers. The positive PCR products were subjected to automated sequencing. Then, nucleotide sequences were aligned with the standard hepatitis B sequence [Gene bank, accession number: AB033559] for mutation detection and analysis.
Results: In this study, three patients (8.1%) were HBeAg-positive and all of them were HBsAg-positive. The mean of CD4 cell count was 120 cells/mL. The mean age of the patients was 36.16 years. The important pathological mutations in HBV patients including 1752A (73%), 1773C (70.3%), 1753C (10.8%), 1896A (8.1%) and 1762T/1764A (2.7%) were detected in this study.
Conclusion: Identification of mutations in co-infected patients is of greater importance compared to mono-infected patients, because it can be useful for prediction of HCC-related mutations. Co-infection with HIV has important effects on the natural history of HBV infection, and creates different mutational patterns compared to mono-infected patients.
Keywords: HBV, HIV, Mutation.
